Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05824169 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 2025 to Dec 2026v4
  2. Re-verified, no change to tracked fieldsv3
  3. Primary endpoints revised (2) Secondary endpoints: details revised at 1 of 3 entriesv2 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 3 entries

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.
Trial Details
NCT Number NCT05824169
Lead Sponsor GeneCradle Inc
Conditions Spinal Muscular Atrophy
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov